Pasar al contenido principal

AVANCES EN TECNICAS DE IMAGEN Y TERAPIA EN DISTROFIAS MUSCULARES: EVALUACION Y TRATAMIENTO DE LA FIBROSIS.

PI18/01525

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2018
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Centro realización IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Corrigendum, Magnetization Transfer Ratio in Lower Limbs of Late Onset Pompe Patients Correlates With Intramuscular Fat Fraction and Muscle Function Tests

  • Nuñez Peralta, Claudia Alejandra|||0000-0002-3235-0799
  • Montesinos, Paula|||0000-0001-6944-7730
  • Alonso-Jiménez, Alicia|||0000-0002-2200-9255
  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Reyes-Leiva, David|||0000-0001-6983-7130
  • Sánchez González, Javier|||0000-0003-1427-3870
  • Llauger, Jaume|||0000-0002-3744-3257
  • Segovia, Sonia
  • Belmonte Jimeno, Izaskun|||0000-0003-0930-6586
  • Pedrosa Hernández, Irene
  • Martínez-Noguera, Antonio
  • Matellini-Mosca, B.
  • Walter, Glenn
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
[This corrects the article DOI: 0.3389/fneur.2021.634766.].
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical and genetic spectrum of a large cohort of patients with δ-sarcoglycan muscular dystrophy

  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • González Quereda, Lidia|||0000-0003-0715-6414
  • Bruno, Claudio
  • Panicucci, Chiara
  • Alavi, Afagh
  • Nafissi, Shahriar
  • Nilipour, Yalda
  • Zanoteli, Edmar
  • Isihi, Lucas Michielon de Augusto
  • Melegh, Béla
  • Hadzsiev, Kinga
  • Muelas, Nuria|||0000-0002-2349-7481
  • Vílchez, Juan J.|||0000-0002-0532-2872
  • Dourado, Mario Emilio
  • Kadem, Naz
  • Kutluk, Gultekin
  • Umair, Muhammad|||0000-0001-6729-9746
  • Younus, Muhammad
  • Pegorano, Elena
  • Bello, Luca|||0000-0002-3075-6525
  • Crawford, Thomas O.
  • Suarez-Calvet, Xavier|||0000-0002-5314-6607
  • Töpf, Ana
  • Guglieri, Michela|||0000-0002-8455-0637
  • Marini-Bettolo, Chiara|||0000-0003-3795-6017
  • Gallano, Pia|||0000-0001-8104-2197
  • Straub, Volker|||0000-0001-9046-3540
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
Sarcoglycanopathies include four subtypes of autosomal recessive limb-girdle muscular dystrophies (LGMDR3, LGMDR4, LGMDR5 and LGMDR6) that are caused, respectively, by mutations in the SGCA, SGCB, SGCG and SGCD genes. Delta-sarcoglycanopathy (LGMDR6) is the least frequent and is considered an ultra-rare disease. Our aim was to characterize the clinical and genetic spectrum of a large international cohort of LGMDR6 patients and to investigate whether or not genetic or protein expression data could predict a disease's severity. This is a retrospective study collecting demographic, genetic, clinical and histological data of patients with genetically confirmed LGMDR6 including protein expression data from muscle biopsies. We contacted 128 paediatric and adult neuromuscular units around the world that reviewed genetic data of patients with a clinical diagnosis of a neuromuscular disorder. We identified 30 patients with a confirmed diagnosis of LGMDR6 of which 23 patients were included in this study. Eighty-seven per cent of the patients had consanguineous parents. Ninety-one per cent of the patients were symptomatic at the time of the analysis. Proximal muscle weakness of the upper and lower limbs was the most common presenting symptom. Distal muscle weakness was observed early over the course of the disease in 56.5% of the patients. Cardiac involvement was reported in five patients (21.7%) and four patients (17.4%) required non-invasive ventilation. Sixty per cent of patients were wheelchair-bound since early teens (median age of 12.0 years). Patients with absent expression of the sarcoglycan complex on muscle biopsy had a significant earlier onset of symptoms and an earlier age of loss of ambulation compared to patients with residual protein expression. This study confirmed that delta-sarcoglycanopathy is an ultra-rare neuromuscular condition and described the clinical and molecular characteristics of the largest yet-reported collected cohort of patients. Our results showed that this is a very severe and quickly progressive disease characterized by generalized muscle weakness affecting predominantly proximal and distal muscles of the limbs. Similar to other forms of sarcoglycanopathies, the severity and rate of progressive weakness correlates inversely with the abundance of protein on muscle biopsy. Alonso-Pérez et al. describe the largest cohort to date of patients with the ultra-rare neuromuscular disorder delta-sarcoglycanopathy, and show that the severity and rate of progressive weakness correlates inversely with the abundance of protein expression on muscle biopsy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Nintedanib Reduces Muscle Fibrosis and Improves Muscle Function of the Alpha-Sarcoglycan-Deficient Mice

  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Carrasco-Rozas, Ana|||0000-0003-2165-8162
  • Borrell-Pages, Maria|||0000-0002-1759-9756
  • Fernández Simón, Esther|||0000-0003-4804-6553
  • Piñol-Jurado, Patricia|||0000-0002-2757-5758
  • Badimon, Lina|||0000-0002-9162-2459
  • Wollin, Lutz|||0000-0002-3617-5772
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Olivé i Plana, Montserrat|||0000-0001-5727-0165
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Suarez-Calvet, Xavier|||0000-0002-5314-6607
Sarcoglycanopathies are a group of recessive limb-girdle muscular dystrophies, characterized by progressive muscle weakness. Sarcoglycan deficiency produces instability of the sarcolemma during muscle contraction, leading to continuous muscle fiber injury eventually producing fiber loss and replacement by fibro-adipose tissue. Therapeutic strategies aiming to reduce fibro-adipose expansion could be effective in muscular dystrophies. We report the positive effect of nintedanib in a murine model of alpha-sarcoglycanopathy. We treated 14 Sgca mice, six weeks old, with nintedanib 50 mg/kg every 12 h for 10 weeks and compared muscle function and histology with 14 Sgca mice treated with vehicle and six wild-type littermate mice. Muscle function was assessed using a treadmill and grip strength. A cardiac evaluation was performed by echocardiography and histological study. Structural analysis of the muscles, including a detailed study of the fibrotic and inflammatory processes, was performed using conventional staining and immunofluorescence. In addition, proteomics and transcriptomics studies were carried out. Nintedanib was well tolerated by the animals treated, although we observed weight loss. Sgca mice treated with nintedanib covered a longer distance on the treadmill, compared with non-treated Sgca mice, and showed higher strength in the grip test. Moreover, nintedanib improved the muscle architecture of treated mice, reducing the degenerative area and the fibrotic reaction that was associated with a reversion of the cytokine expression profile. Nintedanib improved muscle function and muscle architecture by reducing muscle fibrosis and degeneration and reverting the chronic inflammatory environment suggesting that it could be a useful therapy for patients with alpha-sarcoglycanopathy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Isolation of human fibroadipogenic progenitors and satellite cells from frozen muscle biopsies

  • Suarez-Calvet, Xavier|||0000-0002-5314-6607
  • Fernández Simón, Esther|||0000-0003-4804-6553
  • Piñol-Jurado, Patricia|||0000-0002-2757-5758
  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Carrasco-Rozas, Ana|||0000-0003-2165-8162
  • Lleixà, Cinta|||0000-0002-9971-0584
  • López-Fernández, Susana
  • Pons, Gemma|||0000-0001-8803-5432
  • Soria, L.
  • Bigot, Anne|||0000-0003-0337-5425
  • Mouly, V.
  • Illa, Isabel|||0000-0002-2186-2684
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Jaiswal, JK.|||0000-0002-5992-5185
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
Skeletal muscle contains multiple cell types that work together to maintain tissue homeostasis. Among these, satellite cells (SC) and fibroadipogenic progenitors cells (FAPs) are the two main stem cell pools. Studies of these cells using animal models have shown the importance of interactions between these cells in repair of healthy muscle, and degeneration of dystrophic muscle. Due to the unavailability of fresh patient muscle biopsies, similar analysis of interactions between human FAPs and SCs is limited especially among the muscular dystrophy patients. To address this issue here we describe a method that allows the use of frozen human skeletal muscle biopsies to simultaneously isolate and grow SCs and FAPs from healthy or dystrophic patients. We show that while the purified SCs differentiate into mature myotubes, purified FAPs can differentiate into adipocytes or fibroblasts demonstrating their multipotency. We find that these FAPs can be immortalized and the immortalized FAPs (iFAPs) retain their multipotency. These approaches open the door for carrying out personalized analysis of patient FAPs and interactions with the SCs that lead to muscle loss.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Magnetization Transfer Ratio in Lower Limbs of Late Onset Pompe Patients Correlates With Intramuscular Fat Fraction and Muscle Function Tests

  • Nuñez Peralta, Claudia Alejandra|||0000-0002-3235-0799
  • Montesinos, Paula|||0000-0001-6944-7730
  • Alonso-Jiménez, Alicia|||0000-0002-2200-9255
  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Reyes-Leiva, David|||0000-0001-6983-7130
  • Sánchez González, Javier|||0000-0003-1427-3870
  • Llauger, Jaume|||0000-0002-3744-3257
  • Segovia, Sonia
  • Belmonte Jimeno, Izaskun|||0000-0003-0930-6586
  • Pedrosa Hernández, Irene
  • Martínez-Noguera, A.
  • Matellini-Mosca, B.
  • Walter, Glenn
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
Objectives: Magnetization transfer (MT) imaging exploits the interaction between bulk water protons and protons contained in macromolecules to induce signal changes through a special radiofrequency pulse. MT detects muscle damage in patients with neuromuscular conditions, such as limb-girdle muscular dystrophies or Charcot-Marie-Tooth disease, which are characterized by progressive fiber loss and replacement by fatty tissue. In Pompe disease, in which there is, in addition, an accumulation of glycogen inside the muscle fibers, MT has not been tested yet. Our aim is to estimate MT ratio (MTR) in the skeletal muscle of these patients and correlate it with intramuscular fat fraction (FF) and results of muscle function tests. Methods: We obtained two-point axial Dixon and Dixon-MT sequences of the right thigh on a 1.5 Teslas MRI scanner in 60 individuals, including 29 late onset Pompe disease patients, 2 patients with McArdle disease, and 29 age and sex matched healthy controls. FF and MTR were estimated. Muscle function using several muscle function tests, including quantification of muscle strength, timed test quality of life scales, conventional spirometry obtaining forced vital capacity while sitting and in the supine position, were assessed in all patients. Results: MTR was significantly lower in Pompe patients compared with controls (45.5 ± 8.5 vs. 51.7 ± 2.3, Student T-test, p < 0.05). There was a negative correlation between the MTR and FF muscles studied (correlation coefficient: -0.65, Spearman test: p < 0.05). MTR correlated with most of the muscle function test results. We analyzed if there was any difference in MTR values between Pompe patients and healthy controls in those muscles that did not have an increase in fat, a measure that could be related to the presence of glycogen in skeletal muscles, but we did not identify significant differences except in the adductor magnus muscle (48.4 ± 3.6 in Pompe vs. 51 ± 1.3 in healthy controls, Student T-test = 0.023). Conclusions: MTR is a sensitive tool to identify muscle loss in patients with Pompe disease and shows a good correlation with muscle function tests. Therefore, the MT technique can be useful in monitoring muscle degeneration in Pompe disease in clinical trials or natural history studies.